523 related articles for article (PubMed ID: 28161120)
1. Management of Venetoclax-Posaconazole Interaction in Acute Myeloid Leukemia Patients: Evaluation of Dose Adjustments.
Agarwal SK; DiNardo CD; Potluri J; Dunbar M; Kantarjian HM; Humerickhouse RA; Wong SL; Menon RM; Konopleva MY; Salem AH
Clin Ther; 2017 Feb; 39(2):359-367. PubMed ID: 28161120
[TBL] [Abstract][Full Text] [Related]
2. Impact of ritonavir dose and schedule on CYP3A inhibition and venetoclax clinical pharmacokinetics.
Freise KJ; Hu B; Salem AH
Eur J Clin Pharmacol; 2018 Apr; 74(4):413-421. PubMed ID: 29302721
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of Rifampin's Transporter Inhibitory and CYP3A Inductive Effects on the Pharmacokinetics of Venetoclax, a BCL-2 Inhibitor: Results of a Single- and Multiple-Dose Study.
Agarwal SK; Hu B; Chien D; Wong SL; Salem AH
J Clin Pharmacol; 2016 Nov; 56(11):1335-1343. PubMed ID: 26953185
[TBL] [Abstract][Full Text] [Related]
4. Dose adjustment of venetoclax when co-administered with posaconazole: clinical drug-drug interaction predictions using a PBPK approach.
Bhatnagar S; Mukherjee D; Salem AH; Miles D; Menon RM; Gibbs JP
Cancer Chemother Pharmacol; 2021 Apr; 87(4):465-474. PubMed ID: 33398386
[TBL] [Abstract][Full Text] [Related]
5. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.
DiNardo CD; Pratz KW; Letai A; Jonas BA; Wei AH; Thirman M; Arellano M; Frattini MG; Kantarjian H; Popovic R; Chyla B; Xu T; Dunbar M; Agarwal SK; Humerickhouse R; Mabry M; Potluri J; Konopleva M; Pollyea DA
Lancet Oncol; 2018 Feb; 19(2):216-228. PubMed ID: 29339097
[TBL] [Abstract][Full Text] [Related]
6. Effect of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics of venetoclax, a BCL-2 inhibitor, in patients with non-Hodgkin lymphoma.
Agarwal SK; Salem AH; Danilov AV; Hu B; Puvvada S; Gutierrez M; Chien D; Lewis LD; Wong SL
Br J Clin Pharmacol; 2017 Apr; 83(4):846-854. PubMed ID: 27859472
[TBL] [Abstract][Full Text] [Related]
7. Effect of Azithromycin on Venetoclax Pharmacokinetics in Healthy Volunteers: Implications for Dosing Venetoclax with P-gp Inhibitors.
Agarwal SK; Tong B; Bueno OF; Menon RM; Salem AH
Adv Ther; 2018 Nov; 35(11):2015-2023. PubMed ID: 30264382
[TBL] [Abstract][Full Text] [Related]
8. Quantitative Prediction of the Effect of CYP3A Inhibitors and Inducers on Venetoclax Pharmacokinetics Using a Physiologically Based Pharmacokinetic Model.
Freise KJ; Shebley M; Salem AH
J Clin Pharmacol; 2017 Jun; 57(6):796-804. PubMed ID: 28052338
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of Venetoclax, a Novel BCL-2 Inhibitor, in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Non-Hodgkin Lymphoma.
Salem AH; Agarwal SK; Dunbar M; Enschede SL; Humerickhouse RA; Wong SL
J Clin Pharmacol; 2017 Apr; 57(4):484-492. PubMed ID: 27558232
[TBL] [Abstract][Full Text] [Related]
10. Semimechanistic Modeling to Guide Venetoclax Coadministration with Ritonavir and Digoxin.
Alhadab AA; Salem AH; Freise KJ
Clin Transl Sci; 2020 May; 13(3):555-562. PubMed ID: 31961475
[TBL] [Abstract][Full Text] [Related]
11. Optimizing venetoclax dose in combination with low intensive therapies in elderly patients with newly diagnosed acute myeloid leukemia: An exposure-response analysis.
Agarwal S; Gopalakrishnan S; Mensing S; Potluri J; Hayslip J; Kirschbrown W; Friedel A; Menon R; Salem AH
Hematol Oncol; 2019 Oct; 37(4):464-473. PubMed ID: 31251400
[TBL] [Abstract][Full Text] [Related]
12. Effects of oral posaconazole on the pharmacokinetic properties of oral and intravenous midazolam: a phase I, randomized, open-label, crossover study in healthy volunteers.
Krishna G; Moton A; Ma L; Savant I; Martinho M; Seiberling M; McLeod J
Clin Ther; 2009 Feb; 31(2):286-98. PubMed ID: 19302901
[TBL] [Abstract][Full Text] [Related]
13. Clinical evaluation of P-glycoprotein inhibition by venetoclax: a drug interaction study with digoxin.
Chiney MS; Menon RM; Bueno OF; Tong B; Salem AH
Xenobiotica; 2018 Sep; 48(9):904-910. PubMed ID: 29027832
[TBL] [Abstract][Full Text] [Related]
14. Impact of Multiple Concomitant CYP3A Inhibitors on Venetoclax Pharmacokinetics: A PBPK and Population PK-Informed Analysis.
Mukherjee D; Brackman DJ; Suleiman AA; Zha J; Menon RM; Salem AH
J Clin Pharmacol; 2023 Jan; 63(1):119-125. PubMed ID: 35996877
[TBL] [Abstract][Full Text] [Related]
15. Safety and pharmacodynamics of venetoclax (ABT-199) in a randomized single and multiple ascending dose study in women with systemic lupus erythematosus.
Lu P; Fleischmann R; Curtis C; Ignatenko S; Clarke SH; Desai M; Wong SL; Grebe KM; Black K; Zeng J; Stolzenbach J; Medema JK
Lupus; 2018 Feb; 27(2):290-302. PubMed ID: 28691866
[TBL] [Abstract][Full Text] [Related]
16. Venetoclax plus cytochrome P450 inhibitors without ramp-up strategy led to low risk of tumor lysis syndrome in acute myeloid leukemia.
Cheng FM; Tien JZ; Chen TT; Yeh SP; Lin CC
Ann Hematol; 2020 Sep; 99(9):2193-2195. PubMed ID: 32621180
[No Abstract] [Full Text] [Related]
17. Pharmacokinetics of oral posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome.
Krishna G; AbuTarif M; Xuan F; Martinho M; Angulo D; Cornely OA
Pharmacotherapy; 2008 Oct; 28(10):1223-32. PubMed ID: 18823218
[TBL] [Abstract][Full Text] [Related]
18. Clinical Predictors of Venetoclax Pharmacokinetics in Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphoma Patients: a Pooled Population Pharmacokinetic Analysis.
Jones AK; Freise KJ; Agarwal SK; Humerickhouse RA; Wong SL; Salem AH
AAPS J; 2016 Sep; 18(5):1192-1202. PubMed ID: 27233802
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of the BCL-2 Inhibitor Venetoclax in Healthy Chinese Subjects.
Cheung TT; Salem AH; Menon RM; Munasinghe WP; Bueno OF; Agarwal SK
Clin Pharmacol Drug Dev; 2018 May; 7(4):435-440. PubMed ID: 29058801
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of venetoclax in patients with 17p deletion chronic lymphocytic leukemia.
Salem AH; Dunbar M; Agarwal SK
Anticancer Drugs; 2017 Sep; 28(8):911-914. PubMed ID: 28562380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]